Company: DERM
Filing Date: 2025-08-28
Form Type: 424B3
Source: 0001104659-25-084876
Chunk: 28

Company: Journey Medical Corp
Filing Date: 2025-08-28
Form: 424B3
Chunk 28
---
4 that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Our current portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are actively marketed in the U.S. Since inception, we have made significant investments to build out our commercial product portfolios, which we believe, coupled with our experienced dermatology sales leadership team and our recently expanded field sales force, will position our business for growth. As of December 29, 2022, our major actively marketed products, which have been approved by the U.S. Food and Drug Administration (“FDA”) for sale in the United States, include:

| · | Amzeeq® ((minocycline) topical foam, 4% for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and children 9 years and older), acquired and launched in January 2022; |
| · | Zilxi® ((minocycline) topical foam, 1.5% for inflammatory lesions due to rosacea in adults), acquired and launched in January 2022;                                                                                 |

| · | Qbrexza® (a medicated cloth towelette for the treatment of primary axillary 
 hyperhidrosis), acquired and launched in May 2021;                          |

| · | Accutane® (an oral isotretinoin drug for the treatment of severe recalcitrant 
 nodular acne), licensed in July 2020 and launched in March 2021;              |

<div align='center'>2</div>

| · | Ximino® (an oral minocycline drug for the treatment of moderate to severe 
 acne), acquired and launched in August 2019;                              |

| · | Exelderm® Cream and Solution (a broad-spectrum antifungal intended for 
 topical use), acquired and launched in October 2018; and               |

| · | Targadox® (an oral doxycycline drug for adjunctive therapy for severe acne), licensed in March 2015 and launched in October 2016. |

Additionally, we sell three authorized generic products:

| · | minocycline hydrocholoride extended release capsules, launched in April 2020; |
| · | sulconazole nitrate cream and solution, launched in January 2020; and         |

| · | doxycycline hyclate immediate release tablets, launched in May 2018. |

Our Strategy We